Kirchgraber Paul R 4
4 · LABORATORY CORP OF AMERICA HOLDINGS · Filed Apr 3, 2023
Insider Transaction Report
Form 4
Kirchgraber Paul R
CEO, Covance Drug Development
Transactions
- Award
Common Stock
2023-03-30+6,763→ 15,832 total - Tax Payment
Common Stock
2023-03-30$224.70/sh−2,886$648,484→ 12,946 total
Footnotes (2)
- [F1]Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022.
- [F2]Stock withholding to satisfy tax withholding obligations.